Lung Adenocarcinoma Clinical Trial
Official title:
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study
Verified date | February 2020 |
Source | Henan Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, randomized, open, multicenter phase Ⅱ study to evaluate the efficacy of cytokine-induced killer cells combined chemotherapy in stage Ⅳ naive EGFR wild-type lung adenocarcinoma.
Status | Terminated |
Enrollment | 280 |
Est. completion date | September 2018 |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Diagnosed as stage ? naive EGFR wild-type lung adenocarcinoma by image, tissue and/or cytology; or relapse after operation (if the patient received adjuvant chemotherapy and the interval between the last chemotherapy and relapse is at least six months. The detection method of EGFR mutation is ARMS. 2. EML4-ALK fuse gene is negative and the detection of EML4-ALK is FISH or ventana IHC. 3. There should be at least one measurable lesions (by CT or MRI) 4. No other cancer history ( except skin squamous cell carcinoma after surgery) 5. Age between 18 and 75 years old 6. World health organization- Eastern Cooperative Oncology Group Performance Status 0-1 7. Life expectancy more than 3 months and can be followed-up 8. Patients must have adequate organ and marrow functions as defined below: white blood cells: more than 3.5×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than 80×109/L, Hemoglobin more than 90g/L, Serum total bilirubin less than 1.5 folds of the upper normal limit (ULN), Serum glutamic-oxal (o) acetic transaminase: less than 2.5×ULN (if there is liver metastasis less than 5×ULN); Serum creatinine: less than 1.0×ULN, Prothrombin time, Active partial thromboplastin time, Fibrinogen, Thrombin time are in normal ranges. 9. Women of child-bearing period must take effective contraceptive measures during all the time of study. During the period of study the results of blood and urine pregnancy test should be negative. 10. Men should take effective contraceptive measures from the beginning of therapy to one month after the last cycle of chemotherapy. 11. Willing to comply with the ban and constraints for this study protocol specified. 12. Informed consent and willing to participate in this study. Exclusion Criteria: 1. Accepted other study drugs 30 days before the beginning of this study. 2. Brain metastases with clinical symptoms ( with exception of being controlled after radiation) 3. Active viral or bacterial infection and can't be controlled with appropriate anti-infection treatment 4. Known as HIV infection, syphilis serology reaction positive, active hepatitis B virus or hepatitis C virus infection 5. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not be coped with study treatment and monitoring requirements. 6. Known allergy to any kind of component of study drugs 7. Active rheumatic diseases 8. Organ transplant recipients 9. Poor compliance 10. Pregnant women 11. Lactating women |
Country | Name | City | State |
---|---|---|---|
China | Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university | ZhengZhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Henan Cancer Hospital | 150th Hospital of PLA, Anyang Regional Hospital, First Affiliated Hospital of Nanyang Medical College, First People's Hospital of Shangqiu, Hebei Medical University Fourth Hospital, Henan Provincial People's Hospital, Jiaozuo Tumor Hospital, Nanyang Central Hospital, Puyang Oil Field General Hospital, Shanxi Dayi Hospital, Shenma Medical Group General Hospital, Tangshan People's Hospital, The 152th Central Hospital of PLA, Xinyang Central Hospital |
China,
Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33. doi: 10.1007/s00262-012-1260-2. Epub — View Citation
Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol. 2015 Sep;28(1):22-8. doi: 10.1016/j.intimp.2015.05.021. Epub 2015 May 23. Review. — View Citation
Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011 Oct;60(10):1497-502. doi: 10.1007/s00262-011-1060- — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | overall survival time | overall survival time aims at from date of randomization until the date of death from any cause, up to 36 months | from the day of randomization to the day of death, up to 36 months | |
Secondary | time to progression | time to progression points to from date of randomization until the date of first documented progression, up to 24 months | from the day of randomization to the day of first detecting progression, up to 24 months | |
Secondary | objective response rate | the partion of overall remission in total proportion | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT04482829 -
TCM in the Treatment of Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05266846 -
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
|
Phase 2 |